For the greater part of this century an expensive search for human oncogenic viruses has gone on without intermission. Whole institutes have been set up which were dedicated to this vast quest. The original (unrealistic) promise of prevention of the disease by hygiene or mass immunization against oncoviruses dies hard. And there never has been any prospect that a tumour initiated by virus would invite some uniquely more effective treatment. In spite of the recent replacement of herpes simplex virus type 2 by a sequence of numbered strains of human papilloma virus as a mooted 'cause' of carcinoma of the cervix, it is true to say that over 50 years of intensive research has failed to prove that any form of cancer prevalent in the UK is virus-induced.
The second big sink for research funds has been the quest, as hoary and trite as the first, for effective immunotherapy. By the beginning of the 1980s over a quarter of the articles in leading cancer journals were on the topic of tumour immunology, and over 400 registered clinical trials of immunotherapy were in progress; yet it is not established as the optional or preferred treatment for any type of cancer -not even for choriocarcinoma, the one clinical cancer whose potential immunogenicity is certified by its allograft status. Contrary to popular belief, potential or manifest immunogenicity has not been demonstrated in any of a wide variety of naturally-arising experimental animal tumours kept free from superimposed artefactual immunogenicity.
These two idees fixes have surely had a long enough run for their money. It behoves cancer research funding agencies to reinvest the money and endeavour in enterprises whose prospects have not been so decisively closed; their scientific committees need to be more alert to 'enthusiasm masquerading as originality' (Gibbon). H B HEWITI 16 Arnett Way, Rickmansworth, Herts WD3 4DA When is treatment economically justified?
Professor Berlin (December 1990 JRSM, p 811) makes an important point regarding the difficulty reconciling 'thinking in economical terms' and the Hippocratic Oath. However, I fear that this is lost among a number of inaccuracies which serve only to diminish the strength of his argument.
For example, commenting on Jennett and Buxton's discussion paper on 'When is treatment for cancer economically justified?' (January 1990, JRSM, p 25), he states that he was 'rather astonished' to read that 'the utilization of health care resources will (my emphasis) be granted to some and denied to other patients'. However, this is, of course, what is already happening, albeit implicitly. Waiting lists are but one example of rationing of health care. Our aim should be that decisions regarding resource allocation are made explicitly, and not allow them to be made, worst of all, by a process of selective neglect.
Further, Berlin states that active palliation therapy justifies 'significant expenditure', a statement with which almost all would agree. The problem comes in defining 'significant'. The notion of 'cost' in economic terms is not one of 'pounds and pence' alone, but of 'sacrifice'; what other alternative to which resources could have been allocated is forgone by following the chosen option? Attaching a monetary value to this is merely a way of objectively measuring cost and enables comparisons to be made. One possible way of doing this is to consider the cost per QALY of different procedures as Jennett and Buxton discussed, using the QALY as a standard measure of outcome.
The question, then, is not 'how much is the patient worth?'; rather, it is 'how much is the treatment worth?' Medical practitioners are best placed to determine this and should do so in the knowledge that if they do not, it may be done less well by others'. However, that it must be done, perhaps sooner rather than later, should not be in doubt. BMJ 1988; 297:471-2 Gastric sarcoidosis
We read the recent case report on gastric sarcoidosis with interest (January 1991 JRSM, p 50). However, we feel that some of the authors comments on the rarity of gastric involvement in sarcoidosis are erroneous.
Certainly we would agree that symptomatic gastric involvement by sarcoidosis is rare and that isolated gastric sarcoidosis, when the difficult differential diagnosis from granulomatous gastritis must be made, is extremely rare.
However, asymptomatic involvement of the stomach in patients with sarcoidosis is relatively common and occurs in at least 10% of cases'. Endoscopic examination, and in particular the appearance of the gastric mucosa, in these patients may be normal and unless multiple biopsies of apparently normal mucosa are taken the diagnosis may be missed. Failure to appreciate this may have resulted in underdiagnosis of asymptomatic gastric sarcoidosis and the impression that it occurs only rarely. Clin Med 1958; 52:231-4 Schubert and Salieri
C D GEORGE
The recent letter by Schoental discussing the death of Franz Schubert (December 1990 JRSM, p 813) followed one by Jackson concerning Mozart's death (December 1990 JRSM, p 813) . Seeing these two great names so close together on the same printed page reminded me of an interesting story connecting these two musical geniuses. While the actual cause of Mozart's death continues to fascinate people", the possibility that Mozart's contemporary and rival, Italian composer Antonio Salieri, might have had something to do with it has for a long time been a rich source of speculation. Pushkin's 19th century play 'Mozart and Salieri' and more recently Peter Shaffer's hugely successful drama 'Amadeus' have perpetuated the theorizing. The motive attributed to Salieri has usually been his jealousy of Mozart's great talent.
A short biography of Franz Schubert by Percy A Scholes that I read as a youths might perhaps serve
